MedTrace Logo

To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers

NCT02690727 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-11-28

Study results available
· View outcomes & findings →

Summary

This is a single centre, open label, randomized, two-treatment, two-period, two-sequence, single dose crossover food effect study in 18 subjects. The subjects will receive the study medication under either fed or fast during each treatment period.

Conditions

  • Healthy

Interventions

DRUG

RP6530

Single oral dose

Sponsors & Collaborators

  • Rhizen Pharmaceuticals SA

    lead INDUSTRY

Principal Investigators

  • Eric Sicard, M.D · Algorithme Pharma Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02690727 on ClinicalTrials.gov